30-Day Appeals Period
Once the CSAC’s decisions are made public via the PQM website, a 30-day appeals period begins. Any interested party may file an appeal with the Appeals Board during the appeals period.
Spring 2023
Valid for Measure Submission
✖
CSAC Endorsement Meeting
The Consensus Standards Approval Committee (CSAC) will be convened to endorse or decline to endorse candidate measures for the Spring 2023 cycle. The CSAC makes endorsement decisions about candidate measures that have been reviewed by project committees, following the public comment period.
CSAC Endorsement Meeting (Backup Date)
The Consensus Standards Approval Committee (CSAC) will be convened to endorse or decline to endorse candidate measures for the Spring 2023 cycle. The CSAC makes endorsement decisions about candidate measures that have been reviewed by project committees, following the public comment period.
Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy
-
Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) and a current or prior ejection fraction (EF) <40% who are self-identified Black or African Americans and receiving ACEI or ARB and Beta-blocker therapy who were prescribed a fixed-dose combination of hydralazine and isosorbide dinitrate seen for an office visit in the measurement period in the outpatient setting or at each hospital discharge
CBE ID2764e